Oral disease-modifying therapies for relapsing-remitting multiple sclerosis-Reference-Cited by-同舟云学术

Oral disease-modifying therapies for relapsing-remitting multiple sclerosis

Published:2015-01-01 Issue:1 Volume:72 Page:25-38
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Thomas Rachel Hutchins¹,Wakefield Richard A.²

Affiliation:

1. Shelby Baptist Medical Center, Alabaster, AL; at the time of writing she was Assistant Professor of Pharmacy Practice, McWhorter School of Pharmacy, Sanford University, Birmingham, AL

2. St. Dominic-Jackson Memorial Hospital, Jackson, MS; at the time of writing he was Resident, Drug Information Practice, McWhorter School of Pharmacy, Samford University

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/72/1/25/28321217/ajhp0025.pdf

Reference60 articles.

1. Multiple sclerosis;Compston;Lancet,2008

2. Multiple sclerosis;Noseworthy;N Engl J Med,2000

3. The natural history of multiple sclerosis: a geographically based study: observations on the progressive phase of the disease;Kremenchutzky;Brain,2006

4. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria;Polman;Ann Neurol,2011

5. Clinical applications of imaging disease burden in multiple sclerosis: MRI and advanced imaging techniques;Riley;Expert Rev Neurother,2012

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medication persistence among people with multiple sclerosis in Slovenia treated with dimethyl fumarate;Current Medical Research and Opinion;2023-10-09

2. Diseases and Disorders Associated with Immune System;Natural Immunomodulators: Promising Therapy for Disease Management;2023-05

3. A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile;PharmacoEconomics - Open;2021-07-05

4. Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS;Frontiers in Neurology;2021-01-12

5. Usage trend of oral drugs for multiple sclerosis patients in Argentina;Multiple Sclerosis and Related Disorders;2021-01